TY - GEN
T1 - DESIGNING A MURINE MODEL OF HUMAN GLIOBLASTOMA BRAIN TUMOR
T2 - 2022 Design of Medical Devices Conference, DMD 2022
AU - Mess, Griffin
AU - Thombre, Rasika
AU - Kerensky, Max
AU - Curry, Eli
AU - Abhabaglou, Fariba
AU - Alomari, Safwan
AU - Brem, Henry
AU - Theodore, Nicholas
AU - Tyler, Betty
AU - Manbachi, Amir
N1 - Funding Information:
The authors acknowledge funding support from the National Science Foundation (NSF) STTR Phase 1 Award (#: 1938939), 6 © 2021 by ASME Defense Advanced Research Projects Agency (DARPA) Award (#: N660012024075), and Johns Hopkins Institute for Clinical and Translational Research (ICTR)’s Clinical Research Scholars Program (KL2), administered by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS).
Publisher Copyright:
© 2022 by ASME
PY - 2022
Y1 - 2022
N2 - Glioblastoma Multiforme (GBM) is a malignant brain cancer with low overall survival. Therefore, researchers are looking to augment its current therapeutic regimen, which includes surgical tumor resection, chemotherapy and radiation. A promising treatment modality, focused ultrasound, has been used as a non-invasive treatment for GBM through multiple approaches such as thermal ablation, immunomodulation, and blood brain barrier disruption. In order to develop these treatments for clinical trials, testing in animal models needs to be performed to investigate the efficacy of the treatment in complex biological environments, as well as to evaluate any side-effects. The more biologically relevant the animal model is to human anatomy, the more applicable the results will be for translation to clinical trials. Here, we report a human GBM rat model, which utilizes an IDH-wildtype, EGFRvIII mutant patient-derived xenograft in athymic rats. The in vivo tumor growth rate was assessed over a period of 20 days to evaluate reproducibility and to develop the model for future testing of FUS in the treatment of GBM.
AB - Glioblastoma Multiforme (GBM) is a malignant brain cancer with low overall survival. Therefore, researchers are looking to augment its current therapeutic regimen, which includes surgical tumor resection, chemotherapy and radiation. A promising treatment modality, focused ultrasound, has been used as a non-invasive treatment for GBM through multiple approaches such as thermal ablation, immunomodulation, and blood brain barrier disruption. In order to develop these treatments for clinical trials, testing in animal models needs to be performed to investigate the efficacy of the treatment in complex biological environments, as well as to evaluate any side-effects. The more biologically relevant the animal model is to human anatomy, the more applicable the results will be for translation to clinical trials. Here, we report a human GBM rat model, which utilizes an IDH-wildtype, EGFRvIII mutant patient-derived xenograft in athymic rats. The in vivo tumor growth rate was assessed over a period of 20 days to evaluate reproducibility and to develop the model for future testing of FUS in the treatment of GBM.
KW - Glioblastoma
KW - Neuro-oncology
KW - Non-invasive
KW - animal model
KW - focused ultrasound
UR - http://www.scopus.com/inward/record.url?scp=85130247073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130247073&partnerID=8YFLogxK
U2 - 10.1115/DMD2022-1025
DO - 10.1115/DMD2022-1025
M3 - Conference contribution
AN - SCOPUS:85130247073
T3 - Proceedings of the 2022 Design of Medical Devices Conference, DMD 2022
BT - Proceedings of the 2022 Design of Medical Devices Conference, DMD 2022
PB - American Society of Mechanical Engineers
Y2 - 11 April 2022 through 14 April 2022
ER -